Cellular Targeting of Drugs

One of the main challenges in the administration of therapeutic medications is the targeted localization of maximum therapeutic concentrations to the Cellular/Subcellular Site of action in pathologically damaged tissues. Small molecule drugs frequently have a wide range of side effects, lack tissue and organ selectivity, leave the body quickly in vivo, and are especially harmful when combined with chemotherapy. One of the most promising answers to this problem recently has been the use of medicine delivery systems (DDS). In recent years, cell-mediated DDS has come to be recognised as a potential remedy for the aforementioned problems. The advantages of the recently developed therapy branch known as cell-mediated DDS include extending the duration of circulation, reducing cellular and tissue toxicity, and enabling personalised distribution. One example of this are small molecule drugs. One of the main methods for treating cancer is with small molecule drugs. Chemotherapy, which until recently was the only option for treating cancer, has a high level of toxicity and side effects since it cannot tell the difference between cancer cells and healthy cells. The way that cancer is treated has changed significantly over the past 20 years, moving away from broad-spectrum cytotoxic medications and toward tailored therapy. Targeted medications, as opposed to conventional chemotherapy treatments, promise great efficiency and minimal toxicity by selectively eliminating cancer cells while protecting healthy cells. Cancer-targeted therapy can be divided into two basic categories: small compounds and macromolecules/biologics (e.g., monoclonal antibodies, polypeptides, antibody-drug conjugates, and nucleic acids).